[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.146.179.146. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editorial
January 22/29, 2014

Will Detection of MicroRNA Biomarkers in Blood Improve the Diagnosis and Survival of Patients With Pancreatic Cancer?

Author Affiliations
  • 1Division of Radiation Biology, Department of Radiation Oncology, University of Alabama, Birmingham
  • 2Comprehensive Cancer Center, Department of Molecular Virology, Immunology and Medical Genetics, Ohio State University, Columbus
JAMA. 2014;311(4):363-365. doi:10.1001/jama.2013.284665

Pancreatic cancer represents the 10th most commonly diagnosed cancer, but is the 4th leading cause of cancer-related death in the United States.1 It is estimated that approximately 45 220 new cases of pancreatic cancer will be diagnosed and that 38 460 people will die of pancreatic cancer in the United States in 2013,1 with an estimated 227 000 deaths from pancreatic cancer occurring worldwide each year.2 The incidence of pancreatic cancer has been slowly increasing over the last decade.2,3 The 1- and 5-year survival rates for pancreatic cancer are about 25% and 5%, respectively, which are the lowest survival rates of all major cancers.1,3

First Page Preview View Large
First page PDF preview
First page PDF preview
×